期刊文献+

α-香附酮的分离及其解热镇痛作用研究 被引量:28

Study on Isolation of α-Cyperone and Its Analgesic and Antipyretic Effects
下载PDF
导出
摘要 目的研究香附有效成分α-香附酮的解热镇痛作用。方法通过乙醇提取、硅胶柱层析分离、核磁共振等手段进行结构解析,确定中药香附中具有解热镇痛作用的有效成分为α-香附酮。再采用内毒素致家兔发热模型、小鼠醋酸扭体法、热板法实验,考察α-香附酮的药效作用。结果与模型组比较,α-香附酮能降低内毒素致家兔发热的体温(P<0.05),对醋酸所致的小鼠扭体反应有抑制作用(P<0.05),但是对热板法所致的小鼠痛阈反应时间无明显作用(P>0.05)。结论α-香附酮是香附发挥解热镇痛作用的有效成分之一,α-香附酮可能通过外周机制发挥镇痛作用。 Objective To study the antipyretic and analgesic constituents from Rhizoma Cyperi. Methods After effective fraction extraction by petroleum ether, compound isolation by silica gel column chromatography, and structures identification mainly by nuclear magnetic resonance (NMR), α-cyperone was confirmed as the active antipyretic and analgesic ingredient. The antipyretic and analgesic actions of α-cyperone were investigated by applying endotoxin-induced fever rabbit model, writhing method in mice, and thermal stimulation method in mice. Results Compared with the model group, α-cyperone had significant antipyretic effect on rabbits with endotoxin -induced fever(P 〈 0.05), and inhibited acetic acid-induced writhing response in mice (P 〈 0.05), but had no effect on pain threshold time in mice stimulated by hot plate (P 〉 0.05 ). Conclusion eL-Cyperone is one of the main bioactive ingredients in Rhizoma Cyperi, and may be play analgesic effects through peripheral regulation.
出处 《中药新药与临床药理》 CAS CSCD 北大核心 2012年第6期620-623,共4页 Traditional Chinese Drug Research and Clinical Pharmacology
基金 广东省科技计划项目(2010b080701050)
关键词 香附 Α-香附酮 解热 镇痛 Rhizoma Cyperi α -Cyperone Antipyretic Analgesic
  • 相关文献

参考文献5

二级参考文献46

  • 1[1]Lichtenstein D, Syngal S, Wlfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rherm,1995;38:1:5~18.
  • 2[2]Bjarnason I, Macpherson A, Somasundaram S, et al. Lower bowel toxicity of non-steroidal anti-inflammatory drugs. Lewis A: Non-steroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Uses. New York: NY, Marcel Dekker, 1994;145~157.
  • 3[3]Marie R, Griffin, MD. Epidemiology of non-steroidal antiinflammatory drug-associated gastrointestinal injury. Am J Med.1998;104: 23~28.
  • 4[4]Fujiwara Y, Schmassman A, Arakawa T, et al. Indomethacin interferes with epidermal growth factor binding and proliferative response of KATO Ⅲ cells. Digestion, 1995;56:364~369.
  • 5[5]Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales.Gastroenterology. 1993; 104:1083~ 1091.
  • 6[6]Fries JF, Williams CA, Michel BA et al. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med, 1991 ;91:213 ~222.
  • 7[7]Gutthamm SP, García LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and the risk of hospitalization for upper gastrointestinal bleeding and perforation in saskatche wan: a nested case-control study. Pharmacoepidemiol Drug Safety. 1994;3:S63.
  • 8[8]Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term non-steroidal anti-inflammatorydrug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology, 1992;102 :1899~1905.
  • 9[9]Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet, 1994 ;34 3 :107 5-107 8
  • 10[10]Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. am J Med, 1999;106:13~23.

共引文献96

同被引文献409

引证文献28

二级引证文献269

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部